



Catalyst Pharmaceuticals, Inc.
Investor Relations Department
355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: CPRX ¹

Last Trade:	2.75
Trade Time:	4:00 PM ET 06/22/17
Change:	0.04 (1.476%)
Day Range	2.68 - 2.85
52-Week Range	0.68 - 2.73
Volume	1,790,948
Market Cap. (\$M)	230.423
Shares Out (M)	83.790

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Catalyst Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. Catalyst's lead candidate, amifampridine phosphate, for the treatment of LEMS has completed testing in a global, multi-center, double-blinded randomized pivotal Phase 3 trial resulting in positive top-line data. Catalyst has recently filed an NDA for this product seeking approval for its use as a treatment of LEMS and Congenital Myasthenic Syndromes (CMS). Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement disorders associated with the treatment of Parkinson's Disease.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 06/01/17 [Catalyst Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference](#)
- 05/17/17 [Catalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium](#)
- 05/12/17 [Catalyst Pharmaceuticals Receives 2017 Beacon Council Award for Contributions in Life Sciences & Healthcare](#)
- 05/10/17 [Catalyst Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update](#)
- 05/10/17 [Catalyst Pharmaceuticals Announces Poster Presentation of MuSK-MG clinical data at the 13th International Conference on Myasthenia Gravis and Related Disorders](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

- 03/15/17 [Annual Report \(10-K\)](#)
- 04/14/17 [Definitive Proxy Statement](#)
- 05/10/17 [Quarterly Report \(10-Q\)](#)
- 11/09/16 [Quarterly Report \(10-Q\)](#)
- 08/09/16 [Quarterly Report \(10-Q\)](#)